Ebook Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image? 9781118487471 Medicine Health Science Books
Ebook Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image? 9781118487471 Medicine Health Science Books
Download As PDF : Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image? 9781118487471 Medicine Health Science Books
An expert's view on solving the challenges confronting today's pharmaceutical industry
Author John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global RD Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, Drug Truths Dispelling the Myths About Pharma RD, was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being.
As he toured the country discussing Drug Truths, Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities.
Starting with "4 Secrets that Drug Companies Don't Want You to Know," Devalued and Distrusted provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as
- Why pharmaceutical RD productivity has declined
- Where pharmaceutical companies need to invest their resources
- What can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases
- How the pharmaceutical industry can regain public trust and resuscitate its image
Our understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading Devalued and Distrusted, you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges.
Get to know the author Read an interview with John LaMattina or watch a video on ChemistryViews!
Interview John LaMattina 30 Years in Pharma
Video Can the Pharmaceutical Industry Restory its Broken Image?
Ebook Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image? 9781118487471 Medicine Health Science Books
"My brain is aware of what this book calls sedation, dry mouth, and arrhythmia as side effects from some medications that I associate with people in Minneapolis who thought I was crazy and tried to turn me into a highly medicated individual. Our society functions on high mobility, but those who are not mobile try to avoid phone conversations with anyone who is likely to tell us to call 9-1-1 to be taken to someplace where we will be treated for derangement. The F.D.A. failed to approve a combination drug that fools the brain into thinking anything sweet is unappetizing because symptoms arising from old man fat dread are not always the best way to get our society to only 500,000 first-time heart attacks each year. LaMattina calls himself a senior partner who would have occupational glee if only 500,000 Americans had a first-time heart attack each year because they take enough statins to keep from having 510,000 heart attacks. Millions of Americans would be taking pills to reduce the risk factors associated with the way Americans live, eat, and throw what they are not using right now in the trash.
In my lifetime, institutional thinking has assumed that hundreds of millions of Americans can be treated like patients so hundreds of thousands will have extra years of life. I took beta blockers to slow my heartbeat so the heart muscle would not have fatal arrhythmia before I had lived a normal lifespan. I seem young now compared to old people walking around like zombies on pacemakers and former stroke victims. The F.D.A. wants 10,000 users of a new drug to live long enough for five years of test results before we get new forms of brain control that reduce diabetes, cardiovascular events, and the terror of meaningless activities becoming expenses of the last illness that reduce estates."
Product details
|
Tags : Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image? 9781118487471 Medicine Health Science Books @ ,John L. LaMattina,Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image?,Wiley,1118487478,MEDICAL / Pharmacology.,Pharmaceutical industry - Corrupt practices,Pharmaceutical industry;Corrupt practices.,BUSINESS ECONOMICS / Industries / Pharmaceutical Biotechnology,Business Economics/Industries - Pharmaceutical Biotechnology,Chemistry - General,Corrupt practices,Drug Discovery Development,Industries - Pharmaceutical Biotechnology,MEDICAL / Pharmacology,Medical,Medical / Nursing,Pharmaceutical industries,Pharmaceutical industry,Pharmacology,SCIENCE / Chemistry / General,SachbĂ¼cher / Natur, Technik / Naturwissenschaft,Science/Chemistry - General,bisacsh,pharmaceutical, pharmaceutical industry, pharmaceuticals, pharma, medicine, medicines, new medicines, new medicine, RD in pharmaceuticals, pharmaceutical RD, creating safe medicines, John LaMattina, Pfizer president, Human Genome Project, “4 Secrets Drug Companies Don’t Want You to Know”, Improving Pharmaceutical RD Output, Restoring the Image of Pharma, Alzheimer’s Disease, Obesity Diabetes, New Antibiotics, Cancer Research, Cardiovascular Drugs, Impact of FDA on Drug Discovery and Development, Dr. Oz, Outcomes Research,pharmaceutical; pharmaceutical industry; pharmaceuticals; pharma; medicine; medicines; new medicines; new medicine; pharmaceutical R&D; creating safe medicines; John LaMattina; Pfizer president; Human Genome Project; Improving Pharmaceutical RD Output; Alzheimer’s Disease; Obesity Diabetes; Cancer Research; Cardiovascular Drugs; Dr. Oz; Outcomes Research; RD in pharmaceuticals; “4 Secrets Drug Companies Don’t Want You to Know”; Restoring the Image of Pharma; New Antibiotics; Impact of FDA on Drug Discovery and Development
Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image? 9781118487471 Medicine Health Science Books Reviews :
Devalued and Distrusted Can the Pharmaceutical Industry Restore its Broken Image? 9781118487471 Medicine Health Science Books Reviews
- My brain is aware of what this book calls sedation, dry mouth, and arrhythmia as side effects from some medications that I associate with people in Minneapolis who thought I was crazy and tried to turn me into a highly medicated individual. Our society functions on high mobility, but those who are not mobile try to avoid phone conversations with anyone who is likely to tell us to call 9-1-1 to be taken to someplace where we will be treated for derangement. The F.D.A. failed to approve a combination drug that fools the brain into thinking anything sweet is unappetizing because symptoms arising from old man fat dread are not always the best way to get our society to only 500,000 first-time heart attacks each year. LaMattina calls himself a senior partner who would have occupational glee if only 500,000 Americans had a first-time heart attack each year because they take enough statins to keep from having 510,000 heart attacks. Millions of Americans would be taking pills to reduce the risk factors associated with the way Americans live, eat, and throw what they are not using right now in the trash.
In my lifetime, institutional thinking has assumed that hundreds of millions of Americans can be treated like patients so hundreds of thousands will have extra years of life. I took beta blockers to slow my heartbeat so the heart muscle would not have fatal arrhythmia before I had lived a normal lifespan. I seem young now compared to old people walking around like zombies on pacemakers and former stroke victims. The F.D.A. wants 10,000 users of a new drug to live long enough for five years of test results before we get new forms of brain control that reduce diabetes, cardiovascular events, and the terror of meaningless activities becoming expenses of the last illness that reduce estates. - John LaMattina's lengthy career in the pharmaceutical industry had prepared him for close encounters of many kinds, but nothing could have prepared him for his encounter with Dr. Oz. Perhaps it was ignorance that led him to believe that his appearance on one of Dr. Oz's television segments would be relatively benign, but he had another thing coming. Next time, no doubt, LaMattina will ask questions. A lot of them. Undoubtedly shock set in once he realized that he, along with big pharma, was the target of the day. Monstrous villains, evil money-mongers who were only out for one thing ... themselves and that buck. Right on down the yellow brick road LaMattina went in an effort to explain away the "Four Secrets That Drug Companies Don't Want You to Know."
The statements, of course, were inflammatory and LaMattina answered them as best he could. The audience reaction clearly indicated that the questions needed further explanation. This book is a result of those four questions. I had only one problem with this book and that was to keep people from walking off with it before I had finished it. It is not a lengthy tome and in fact it can be read in a day if one is so inclined. It is written with the layman in mind, yet has sufficient references for those who wish to explore the topic further. The risks to the public, who may have decided to discard prescribed medications as a result of the show, were plentiful. LaMattina lamented that "oftentimes diet and exercise are not sufficient to reduce the risk of these diseases [diabetes, osteoarthritis, osteoporosis, etc.]; and at some point specific medicines may be required to restore a person's health to prevent long-term consequences of the disease." (p. 15)
LaMattina decided to discuss many of the issues big pharma faces, particularly in R & D. The first thought that came to mind was that he would be biased wholly toward pharma, but I found the discussion to be extremely informative without being inflammatory. He fully acknowledges the shortcomings of the industry, but also is quick to point our "the value the biopharmacceutical industry adds to improving the world's health." (p.58) Historically, the discussion mainly focuses on the last decade, but has snippets relative to what is going on today. I found his insight to be invaluable, particularly because of his insider view of the pharmaceutical industry as the former president of Pfizer's Global R & D Division.
I felt LaMattina sat down and asked himself those difficult questions we all are curious about. I ended up being quite enamored with this book and learned much more than I ever thought I would (or would want to) about the big pharma and R & D. The writing was in what I call a conversational format. The let-me-tell-you-about-what-I-know attitude had me mesmerized. I definitely came away feeling more comfortable with the industry and LaMattina left few stones unturned. It was probably a good thing that he never asked what Dr. Oz's segment was about or we wouldn't have this amazing book.
"Four Secrets That Drug Companies Don't Want You to Know."
1. Drug companies underestimate dangerous side effects.
2. Drug companies control much of the information your doctor gets.
3. You're often prescribed drugs that you don't need.
4. Drugs target the symptoms, not the cause.
CHAPTER 1 THE FOUR SECRETS THE DRUG COMPANIES DON'T WANT YOU TO KNOW
Drug Companies Underestimate Dangerous Side Effects
Drug Companies Control Much of the Information Your Doctor Gets
You're Often Prescribed Drugs That You Don't Need
Drugs Target the Symptoms, Not the Cause
Conclusion
References
CHAPTER 2 WHAT HAS HAPPENED TO R&D PRODUCTIVITY?
Impact of Mergers on R&D Productivity
Heightened FDA Requirements for NDAs
Higher Hurdles Set by Payers
Conclusion
References
CHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH
Cancer
Diseases of the Brain
Cardiovascular Disease (CVD)
Diabetes
Bacterial Infections
Conclusion
References
CHAPTER 4 IMPROVING R&D OUTPUT
The Views of Others
Pharma's Blockbuster Mentality Needs to Change
Can "Predictive Innovation" Lead to Greater Success Rates?
Would Royalties Make Scientists More Productive?
Will Drug Repositioning Help Fill the R&D Pipeline?
Consultants Don't Always Have the Facts
Personal Views
Discovery Must Focus on Productivity
Does Size Help or Hinder R&D Productivity?
To Outsource or Not to Outsource? That's the Pharma R&D Question
Big Pharma Early Research Collaborations
Conclusion
References
CHAPTER 5 RESTORING PHARMA'S IMAGE
Illegal Detailing of Drugs
Pharmaceutical Companies Should Drop TV Ads
The Need for Greater Transparency
How Committed Is Big Pharma to Rare Diseases?
Pharmaceutical Companies and Philanthropy
Pharma Needs to Have Its Scientists Tell Their Stories
Conclusion
References
CHAPTER 6 FINAL THOUGHTS
References
INDEX - John LaMattina is a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R&D Division, an ultimate insider of the pharmaceutical world. While there is much I dislike about the pharmaceutical industry, it is very interesting to read his account.
However his critique of traditional remedies is fraught with inaccuracies. For example the use of Ginkgo biloba leaves for cognitive impairment is not a traditional use- the Chinese never significantly used ginkgo leaves and this use was derived from the modern German pharmaceutical industry which is far more open to botanical treatments than the US. While it showed little effect for people of normal cognition as he rightly points out, smaller trials show some advantage for people with Alzheimer's.
He points out that cysteine has a weaker effect at stopping smoking than Chantix, which is true. But unlike Chantix it doesn't have the psychopathological effects that I have seen in my own family members who attempted to use it to stop smoking. While he never points out the serious side effects of Chantix, now (but not initially) in the required list of side effects read in television commercials (always listen with your eyes closed to avoid distracting calming pictures) a lower efficacy is better than iatrogenic mental disease.
He is also a strong proponent of statins, citing much lower side effects than I see clinically (which makes me suspicious of the statistics cited.) But since statins can cause diabetes, muscle dysfunction and can clog liver CYP450 liver pathways, prescribing them is not the slam dunk he believes.
Much more interesting are his suggestions for managing R&D and improving the reputation of the industry by stopping the illegal detailing of drugs to doctors for unapproved uses, pulling all television ads (the side effect list is one reason why), engaging in greater transparency (the drug lawyers will howl), greater commitment to rare diseases and greater publicity of the stories of the science of drug discovery. He also decries mergers and acquisitions of companies researching new drugs- corporate cultures often are different and scientists are laid off to avoid duplication, usually to the detriment of R&D.
Comments
Post a Comment